Mercer Global Advisors
TGTX icon

Mercer Global Advisors’s TG Therapeutics TGTX Stock Holding History

Mercer Global Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$789K Buy
14,362
+6,866
+92% +$281K ﹤0.01% 1935
2026
Q1 		$249K Buy
7,496
+279
+4% +$8.31K ﹤0.01% 2620
2025
Q4 		$212K Buy
+7,217
New +$236K ﹤0.01% 2520
2021
Q2 		– Sell
-205
Closed -$10K – 1742
2021
Q1 		$10K Buy
+205
New +$9.85K ﹤0.01% 1616

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Mercer Global Advisors's TGTX Position: Q2 2026 in Review

Mercer Global Advisors increased its TG Therapeutics (TGTX) stake by 92% in Q2 2026, buying an estimated $281K and bringing the position to 14,362 shares worth $789K. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

Mercer Global Advisors first reported a position in TGTX in Q1 2021 and has held it in 4 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Mercer Global Advisors held 14,362 shares of TG Therapeutics worth $789K as of Q2 2026.
  • Mercer Global Advisors bought 6,866 TG Therapeutics shares in Q2 2026, an estimated $281K.
  • TG Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1935 holding.
  • Mercer Global Advisors first reported a position in TG Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.